Global Cancer Peptide Drugs Market Cancer Peptide Therapeutics Clinical Trials Market Forecast 2030

(MENAFN- GlobeNewsWire - Nasdaq) Cancer Peptide market Opportunity To Surpass US$ 18 Billion By 2030 Says Kuick Research

Delhi, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:

• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: > 230 Drugs
• Insight On Commercially Approved Peptide Cancer By Brand Name, Company and Indication

Download Report:

The global cancer peptide therapeutics market is experiencing significant growth as peptides gain recognition as effective, targeted therapies for cancer treatment. Peptides, which are short chains of amino acids, offer several advantages over traditional cancer treatments like chemotherapy and radiation, which can harm healthy tissues and cause severe side effects. Peptides can be designed to specifically bind to cancer cells, minimizing off-target effects and reducing toxicity, while also offering the ability to deliver drugs or imaging agents directly to tumor sites with high precision.

Traditional cancer treatments such as chemotherapy and radiation are effective in killing cancer cells, but they also damage healthy cells, leading to various side effects. Immunotherapy, while promising, may not be effective for all cancer types and is often costly and difficult to access. Peptides, however, combine the specificity of biologics with the simplicity and cost-effectiveness of small molecules, making them a highly attractive alternative. They can be engineered to enhance immune responses, inhibit tumor growth, and improve drug delivery, offering a solution to the complex nature of cancer.

Currently, over 30 peptide-based drugs, such as Goserelin and satumomab pendetide, are approved for cancer treatment and diagnostic use, respectively. Peptides also have applications in diagnostic imaging, such as radiolabeled peptides that help locate tumors, guiding treatment decisions. The concept of theranostics, where peptides are used for both diagnosis and therapy, represents a significant advancement in cancer care. Examples of peptide therapeutics include Lutathera (Lu-177 Dotatate), a radiolabeled peptide for treating neuroendocrine tumors, and Pluvicto (Lutetium-177 vipivotide tetraxetan), used in prostate cancer treatment.

The peptide therapeutics market is led by major pharmaceutical companies like Novartis and Roche, which leverage their expertise in biologics and small molecules to develop and commercialize these therapies. However, smaller biotech firms and startups are also emerging, developing innovative peptide-based cancer treatments. An example of this is Orbis Medicines, which was launched in February 2024, with a focusing on developing peptide drugs using its proprietary macrocycle technology platform.

The US has emerged as the global leader in cancer peptide therapeutics research and development, supported by a robust ecosystem of academic institutions, research centers, and pharmaceutical companies. The US FDA has played a critical role in expediting the approval process for peptide-based therapies, facilitating their clinical translation. For instance, the FDA granted the breakthrough designation to AlphaMedix in February 2024 for the treatment of adult patients with unresectable or metastatic, progressive SSTR+ gastroenteropancreatic neuroendocrine tumors. US-based companies, both large and small, are at the forefront of developing new peptide-based treatments and diagnostic tools.

The peptide therapeutics market is expanding rapidly, with over 250 peptide-based candidates currently in clinical trials targeting a variety of cancers, including breast, lung, prostate, and pancreatic cancers. These peptides are being developed for various mechanisms such as direct tumor targeting, immune modulation, and enhancing chemotherapy delivery. The success of these therapies in clinical trials will determine the future of the peptide therapeutics market, which promises to provide more personalized, targeted, and less toxic cancer treatment options.

As the field continues to evolve, the role of peptide-based therapies in cancer treatment is expected to grow, driven by advancements in peptide synthesis, drug delivery technologies, and clinical outcomes. The market holds great promise for improving cancer care and offering hope for more effective treatments.

MENAFN25112024004107003653ID1108921934